Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension

References

• Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest126(1 Suppl.), 7S–10S (2004).
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.43(12 Suppl.), S40–S47 (2004).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J. Am. Coll. Cardiol.53, 1–43 (2009).
   PubMedGoogle Scholar
• Park MH. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheter Cardiovascular Intervention71(2), 205–213 (2008).
   PubMed Web of Science ®Google Scholar
• Yuan JXJ, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation111, 534–538 (2005).
   PubMedGoogle Scholar
• Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med.107, 216–223 (1987).
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Ann. Intern. Med.115, 343–349 (1991).
   PubMed Web of Science ®Google Scholar
• Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin. Chest Med.23(1), 1–22 (2007).
   Google Scholar
• Thenappan T, Shah SJ, Rich S. A USA-based registry for pulmonary arterial hypertension: 1982–2006. Eur. Respir. J.30, 1103–1110 (2007).
   PubMed Web of Science ®Google Scholar
• Humber M. Update in pulmonary arterial hypertension 2007. Am. J. Respir. Crit. Care Med.177, 574–579 (2008).
   PubMedGoogle Scholar
• Simonneau G, Robbins, IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.54, S43–S54 (2009).
   PubMed Web of Science ®Google Scholar
• Channick RN, Olschewski H, Seeger W et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol.48, 1433–1437 (2006).
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Reichenberger F, Enke B et al. Acute effects of the combination of sildenafil and inhaled treprostinil on hemodynamics and gas exchange in pulmonary hypertension. Pulm. Pharmacol. Ther.21, 824–832 (2008).
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol.55, 1915–1922 (2010).
   PubMed Web of Science ®Google Scholar
• Ewert R, Schaper C, Halank M et al. Inhalative iloprost-pharmacology and clinical application. Expert Opin. Pharmacother.10(13), 1–13 (2009).
   PubMed Web of Science ®Google Scholar
• Gryglewski RJ. Prostacyclin among prostanoids. Pharmacol. Rep.60, 3–11 (2008).
   PubMed Web of Science ®Google Scholar
• Bos CL, Richel DJ, Ritsema T et al. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol.36, 1187–1205 (2004).
   PubMed Web of Science ®Google Scholar
• Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med.104(1), 9–21 (2009).
   PubMed Web of Science ®Google Scholar
• Beghetti M, Reber G, de Moerloose P et al. Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation. Eur. Respir. J.19(3), 518–524 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer CA, Kappa JR, Sinha AK et al. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. J. Lab. Clin. Med.109(2), 184 (1987).
   PubMedGoogle Scholar
• McLaughlin VV, Presberg KW, Doyle RL et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest126, 78–92 (2004).
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simonneau G. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest131, 1917–1928 (2007).
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. J. Cardiol.37, 110–111 (2001).
   PubMedGoogle Scholar
• McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension. Chest126, 145–305 (2004).
   Google Scholar
• Qutayba H, Shannon J, Martin J. Physiological basis of respiratory disease. Eur. Respir. J.27, 243 (2006).
   Google Scholar
• Mclaughlin V, McGoon M. Pulmonary arterial hypertension. Circulation114(13), 1417–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol.35, 176–182 (2000).
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost admininstered by either infusion or inhalation. Eur. Heart J.24, 356–365 (2003).
   PubMed Web of Science ®Google Scholar
• Blumberg FC, Riegger GAJ, Pfeifer M. Hemodynamic effects of aerosolized iloprost in pulmonary hypertension at rest and during exercise. Chest121, 1566–1571 (2002).
   PubMed Web of Science ®Google Scholar
• Cowley AJ, Heptinstall S, Hamptom JR. Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behavior in man. J. Thromb. Haemost.53(1), 90–94 (1985).
   Google Scholar
• Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med.347, 322–329 (2002).
   PubMed Web of Science ®Google Scholar
• Macherndl S, Kneussl M, Baumgartner H et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur. Respir. J.17(1), 8–13 (2001).
   PubMedGoogle Scholar
• Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J.28, 691–694 (2006).
   PubMed Web of Science ®Google Scholar
• Opitz CF, Wensel R, Winkler R et al. Clinical efficacy and survival with inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J.26, 1895–1902 (2005).
   PubMed Web of Science ®Google Scholar
• Clapp LH, Finney P, Turcato S et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol.26(2), 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Schulz A, Ghofrani HA et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J. Pharmacol. Exp. Ther.303(2), 741–745 (2002).
   PubMed Web of Science ®Google Scholar
• Gessler T, Schmehl T, Hoper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur. Respir. J.17, 14–19 (2001).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rose F, Scermuly R et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol. Ther.102, 139–153 (2004).
   PubMed Web of Science ®Google Scholar
• Grant SM, Goa KL. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures. Drugs43(6), 889–924 (1992).
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Wagstaff JA. Inhaled iloprost in primary pulmonary hypertension. Drugs64, 763–773 (2004).
   PubMedGoogle Scholar
• Krause W, Krais T. Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers. Eur. J. Clin. Pharmacol.32, 597–605 (1987).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices in severe pulmonary hypertension. Chest124, 1294–1304 (2003).
   PubMed Web of Science ®Google Scholar
• Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med.124, 820–824 (1996).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med.342, 1866–1870 (2000).
   PubMed Web of Science ®Google Scholar
• Krug S, Seyfarth H, Hagedorff A, Wirtz H. Inhaled iloprost for hepatopulmonary syndrome: improvement of hypoxemia. Eur. J. Gastroenterol. Hepatol.19, 1140–1143 (2007).
   PubMedGoogle Scholar
• Hildebrand M, Krause W, Angeli P et al. Pharmacokinetic of iloprost in patients with hepatic dysfunction. Int. J. Clin. Pharmacol. Ther. Toxicol.10, 430–434 (1990).
   Google Scholar
• Minder S, Fischler M, Muellhaupt B et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur. Respir. J.24, 703–707 (2004).
   PubMed Web of Science ®Google Scholar
• Hildebrand M, Krause W, Fabian H et al. Pharmacokinetics of iloprost in patients with chronic renal failure and on maintenance hemodialysis. Int. J. Clin. Pharmacol. Res.10, 285–292 (1990).
   PubMedGoogle Scholar
• Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary arterial hypertension in children. Vasc. Health Risk Manag.5, 325–331 (2009).
   PubMedGoogle Scholar
• Huang S, Desantis ERH. Treatment of pulmonary arterial hypertension in pregnancy. Am. J. Health Syst Pharm.64, 1922–1925 (2007).
   PubMed Web of Science ®Google Scholar
• Wong PS, Constantinides S, Kennedy CR et al. Primary pulmonary hypertension in pregnancy. J. R. Soc. Med.94, 523–526 (2001).
   PubMedGoogle Scholar
• Winterhalter M, Simon A, Fischer S et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J. Cardiothorac. Vasc. Anesth.22, 406–413 (2008).
   PubMed Web of Science ®Google Scholar
• Petkov V, Ziesche R, Mosgoeller W et al. Aerosolized iloprost improves pulmonary hemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax56, 734–736 (2001).
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.174, 1257–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur. Respir. Rev.18, 2–34 (2009).
   Google Scholar
• Olschewski H, Hoper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 2010104, 731–740 (2004).
   Google Scholar
• Olschewski H, Nikkho S, Behr J et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost. Eur. Heart J.24, 482 (abstract 2567) (2003).
   Google Scholar
• Ghofrani HA, Friese G, Discher T et al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur. Respir. J.23, 321–326 (2004).
   PubMed Web of Science ®Google Scholar
• Cicalili S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr. HIV Res.7, 589–596 (2009).
   PubMedGoogle Scholar
• Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS22, S55–S62 (2008).
   PubMed Web of Science ®Google Scholar